Roger Attick has become president, CEO, and a director of Evergreen, Colo.-based CeMines. In addition, former CEO Bailey Dotson has become vice chairman of the board of directors, and former president Richard Cavalli will remain chairman of the board. Attick has been a venture partner with Artiman Ventures since 2000. He studied electrical engineering at the University of Arizona.
Yasuhiro Kuroda has become business manager of Geneva Bioinformatics and will head the Swiss company’s new Tokyo branch (see briefs, p. 9). Kuroda also represents two other Swiss bioinformatics organizations in Japan. Most recently, he held various positions with Japanese companies Infocom and Teijin Systems Technology. Kuroda received a PhD in pharmaceutical science and a BS in plant genetics from Yokohama City University.
Michael Olex has become vice president of manufacturing for BioTrove. He joins the company from US Genomics, where he was senior vice president for manufacturing and operations. Olex holds an MS in electrical engineering from Cleveland State University, an MBA from Case Western Reserve University, and a BS in electrical engineering from the University of Detroit.
Katherine Webster has joined Biotage-Biosystems as vice president of sales and marketing for North America. Prior to joining the Westborough, Mass.-based company, she was director of sales development at Molecular Staging. Webster holds a BS in chemistry from SUNY College of Environmental Science and Forestry.
Jeffrey Williams in March resigned as president of Genomic Solutions, a subsidiary of Harvard Bioscience. He also resigned as a member of the Harvard Bioscience board. He is now CEO of HandyLab (see story, p. 1). David Strack has replaced him as president. Strack was vice president of sales and marketing at Genomic Solutions, and remains president of Harvard Bioscience’s subsidiary Union Biometrica.
In addition, Neal Harte has joined Harvard Bioscience’s board, replacing Christopher Dick, who resigned. Neal was previously executive vice president and vice chairman of Vitale, Caturano and Company.
Ian Lennox has resigned as group president and CEO, pharmaceutical and biotech markets, at MDS. He will leave the company at the end of May. MDS also announced last week that it is creating a chief operating officer position, but did not say who would fill it.